1 |
Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004;351:2310-2317.
DOI
ScienceOn
|
2 |
Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64.
|
3 |
Memarzadeh F, Ying-Lai M, Chung J, Azen SP, Varma R; Los Angeles Latino Eye Study Group. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2010; 51:2872-2877.
DOI
ScienceOn
|
4 |
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117:1094-1101.
DOI
ScienceOn
|
5 |
Hayreh SS. Management of ischemic optic neuropathies. Indian J Ophthalmol 2011;59:123-136.
|
6 |
Hayreh SS, Podhajsky PA, Zimmerman MB. Retinal artery occlusion: associated systemic and ophthalmic abnormalities. Ophthalmology 2009;116:1928-1936.
DOI
ScienceOn
|
7 |
Hogg RE, Woodside JV, Gilchrist SE, et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008;115:1046-1052.
DOI
ScienceOn
|
8 |
Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974;268:336-345.
DOI
ScienceOn
|
9 |
Van den Born BJ, Hulsman CA, Hoekstra JB, Schlingemann RO, van Montfrans GA. Value of routine funduscopy in patients with hypertension: systematic review. BMJ 2005;331:73.
DOI
ScienceOn
|
10 |
Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992.
DOI
ScienceOn
|
11 |
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
|
12 |
National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. London: Royal College of Physicians (UK); 2011 Aug. Available from : http://www.ncbi.nlm.nih.gov/books/NBK83274.
|
13 |
Grosso A, Veglio F, Porta M, Grignolo FM, Wong TY. Hypertensive retinopathy revisited: some answers, more questions. Br J Ophthalmol 2005;89:1646-1654.
DOI
ScienceOn
|
14 |
Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol 1983;118:213-227.
|
15 |
Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 1988;128: 700-710.
|
16 |
Risk factors for neovascular age-related macular degeneration: the Eye Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-1708.
DOI
ScienceOn
|
17 |
Antioxidant status and neovascular age-related macular degeneration: Eye Disease Case-Control Study Group. Arch Ophthalmol 1993;111:104-109.
DOI
ScienceOn
|
18 |
Saif MW, Mehra R. Incidence and management of bevacizumab- related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5:553-566.
DOI
ScienceOn
|
19 |
West SK, Rosenthal FS, Bressler NM, et al. Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol 1989;107:875-879.
DOI
ScienceOn
|
20 |
Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de Jong PT. C-reactive protein level and risk of aging macula disorder: the Rotterdam Study. Arch Ophthalmol 2007;125:1396-1401.
DOI
ScienceOn
|
21 |
Arevalo JF, Sanchez JG, Wu L, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization in agerelated macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology 2010;117:1974-1981.
DOI
ScienceOn
|
22 |
Dielemans I, Vingerling JR, Algra D, Hofman A, Grobbee DE, de Jong PT. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population: the Rotterdam Study. Ophthalmology 1995;102:54-60.
|
23 |
Klein BE, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005;89:284-287.
DOI
ScienceOn
|
24 |
Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma: a population-based assessment. Arch Ophthalmol 1995;113:216-221.
DOI
ScienceOn
|
25 |
Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000;107:1287-1293.
DOI
ScienceOn
|
26 |
Kaiser HJ, Flammer J. Systemic hypotension: a risk factor for glaucomatous damage? Ophthalmologica 1991;203:105-108.
DOI
ScienceOn
|
27 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ 1998;317:703-713. Erratum in: BMJ 1999;318:29.
DOI
ScienceOn
|
28 |
Wong TY, Larsen EK, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health Studies. Ophthalmology 2005;112:540-547.
DOI
ScienceOn
|
29 |
Wong TY, Scott IU. Clinical practice: retinal-vein occlusion. N Engl J Med 2010;363:2135-2144.
DOI
ScienceOn
|